Developed by VHIO’s Radiomics Group in close collaboration with researchers of the Neuro-Radiology Unit at the Bellvitge University Hospital (HUB),…
featured news
Honoring the legacy of Heine Hoi Hansen and his global contribution to lung cancer research and education, the Heine H….
Today, February 29th is celebrated World Rare Disease Day with the aim of raising awareness in society about these pathologies…
The predictability of response criteria remains controversial in drug development. Numerous reviews and meta-analyses continue to question the reliability of…
Josep Tabernero, Director of VHIO, has been awarded as a Fellow of the American Society of Clinical Oncology (FASCO). This…
Recently published in Nature Protocols, VHIO’s Francisco Barriga and co-author Scott W. Lowe at the Memorial Sloan Kettering Cancer Center,…
Recently published in the journal Nature Medicine (1), results of exploratory research from the open-label phase III INTRIGUE clinical trial…
The Vall d’Hebron Institute of Oncology (VHIO) has received 52 grants this year for its research and technical staff that…
Cancer patients in Europe are treated by an array of different specialties and professions: medical oncologists, radiation oncologists, surgical oncologists,…
Developed in-house by VHIO-born spin-off company Peptomyc, OMO-103 is a mini-protein targeting the MYC oncogene which is found deregulated in…
